NCT03119636View on ClinicalTrials.gov

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

December 31, 2020

Conditions
Parkinson's Disease
Interventions
BIOLOGICAL

NPC transplantation

The cells are stereotactically implanted in the striatum.

DRUG

Levodopa

Levodopa is used depending on the patient's condition

Trial Locations (1)

450052

RECRUITING

The first affiliated hospital of Zhengzhou university, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Chinese Academy of Sciences

OTHER_GOV

NCT03119636 - Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease | Biotech Hunter | Biotech Hunter